Howard Marks
Oaktree Capital Management
Howard Marks BioXcel Therapeutics Inc stake
total: 853
Oaktree Capital Management BTAI trades
- Total transactions:
- 2
- New positions:
- 1
- Added:
- 1
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Howard Marks holds 1,380,248 BioXcel Therapeutics Inc (BTAI) shares with a market value of roughly $1.95M accounting for 0.04% of the overall portfolio. To date, the estimated cost basis is nearly $1.48 for "buy" trades. Oaktree Capital Management first purchased BTAI in 2025 Q2, initially acquiring 241,188 shares. Since the initial investment in BioXcel Therapeutics Inc (BTAI), Oaktree Capital Management has made 1 more transaction.
When did Howard Marks buy BioXcel Therapeutics Inc (BTAI)?
Howard Marks first invested in BioXcel Therapeutics Inc (BTAI) in 2025 Q2 at the reported quarter-end price of $1.81 per share.
What's the cost basis of Oaktree Capital Management's BTAI stake?
The estimated cost basis for BioXcel Therapeutics Inc (BTAI) stake is around $1.48 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $1.48
Howard Marks's historical trades in BioXcel Therapeutics Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.04%
|
1,380,248
|
$1.41
|
$1,946,150
|
+472.27% (+1,139,060)
|
+0.03%
|
|
2025 Q2
|
0.01%
|
241,188
|
$1.81
|
$436,551
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.